# Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE)

> **NCT04058028** · PHASE2 · COMPLETED · sponsor: **Amgen** · enrollment: 244 (actual)

## Conditions studied

- Systemic Lupus Erythematosus (SLE)

## Interventions

- **DRUG:** Rozibafusp Alfa
- **DRUG:** Placebo for Rozibafusp Alfa

## Key facts

- **NCT ID:** NCT04058028
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-02-19
- **Primary completion:** 2023-07-25
- **Final completion:** 2023-07-25
- **Target enrollment:** 244 (ACTUAL)
- **Last updated:** 2024-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04058028

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04058028, "Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE)". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT04058028. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*